Highlights Newsletter 3
This newsletter presents you the following key sessions:
2. Clinical and molecular characteristics of long-term survivors in the CASPIAN trial
3. Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutated lung adenocarcinoma
4. Furmonertinib superior to gefitinib as first-line treatment for EGFR-mutated NSCLC